


# Synthesis of the PMB Ether of 5,6-Epoxyisoprostane E2 through Aldol Reaction of the $\alpha$ -Bromocyclopentanone

Hidehisa Kawashima and Yuichi Kobayashi\*

Department of Bioengineering, Tokyo Institute of Technology, Box B52, Nagatsuta-cho 4259, Midori-ku, Yokohama 226-8501, Japan

## Supporting Information

**ABSTRACT:** 5,6-Epoxyisoprostane E2 was synthesized via bromohydration of the cyclopentene and aldol reaction of the  $\alpha$ -bromocyclopentanone with the epoxyaldehyde. High regioselectivity in the bromohydration was attained with recrystallized NBS and pyridine in aqueous DMSO. The enolate for the aldol reaction was generated by adding *t*-BuLi to the mixture of the  $\alpha$ -bromocyclopentanone and  $\text{ZnI}_2$ . This aldol protocol was applied successfully to several cyclopentanones and aldehydes.



Oxidation products of 1-palmitoyl-2-arachidonoyl-*sn*-glycero-3-phosphocholine (PAPC) have been isolated from rabbit atherosclerotic lesions, mildly oxidized low-density lipoproteins (ox-LDL), and autoxidized PAPC.<sup>1,2</sup> The oxidation products were separated by LC/MS, and the two of them were identified as those that possess 5,6-epoxyisoprostanes E2 and A2 at the *sn*-2 position of the phospholipid. Based on UV analysis, the other compounds were suggested to be the stereo- and regioisomers of 5,6-epoxyisoprostanes E2 and A2. The relative stereochemistry of 5,6-epoxyisoprostane A2 was assigned as 5 by total synthesis<sup>3</sup> (Figure 1),




Figure 1. 5,6-PEIPC, -PEIPC, and related compounds.


and the Yamaguchi esterification with lyso-PC afforded 5,6-PEIPC (4).<sup>3,4</sup> Subsequently, 5,6-PEIPC (1), with the absolute structure (as depicted in Figure 1), was synthesized and the occurrence of 1 in the oxidation products was identified by HPLC and MS analysis,<sup>5</sup> thus establishing the *trans* stereochemistry between the epoxide part and the 2-octenyl chain as is seen in 5. Compounds 1 and 4 have been reported to increase the production of pro-inflammatory mediators—interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1).<sup>2</sup> In contrast, recent biological studies with synthesized 1, 2, 4, and 5 showed that these compounds

exhibit anti-inflammatory activity by suppressing IL-6 and IL-12 production.<sup>6</sup> Taken together, these results suggest that further studies of these products as well as their stereo- and regioisomers are needed to better understand their biological roles.<sup>7</sup>

To support such biological investigations, the development of an efficient synthesis of these compounds is the subject of organic synthesis. After synthesizing 5,6-PEIPC (4) and its regioisomer,<sup>3,4</sup> we have shifted our focus toward synthesis of the PMB derivative of 2, i.e., 3, which is esterified to 5,6-PEIPC (1) by Jung.<sup>5b</sup> Herein, a new protocol for aldol reaction of  $\alpha$ -bromocyclopentanones with aldehydes was developed and successfully utilized for the synthesis of 3.

Previously, Stork<sup>8</sup> developed a scheme for the conversion of olefin A to aldol F (Scheme 1), in which the key reactions were the bromohydration of olefin A (eq 1) and aldol reaction of  $\alpha$ -bromocyclopentanone D (eq 2). This strategy was used in the recent synthesis of ophiobolin A, in which the two substituents are *cis* oriented (diastereomer of A).<sup>9</sup> Regarding the regioselectivity of the bromohydration, pure B was obtained by Stork,<sup>8</sup> while a ca. 5:1 ratio of B and C


## Scheme 1. Highlights of the Present Study



Received: March 3, 2014

Published: April 24, 2014

## Scheme 2. Synthesis of the 5,6-Epoxyisoprostanes E2 Derivative



was described by Walker,<sup>10</sup> who converted **B** to the prostaglandin-like heterocycles via **D**. In the present study, the motif **A** occurs in the form of the PMB ether **13** (Scheme 2).

We envisaged a Claisen rearrangement on **8** as a means of installing the requisite side chain shown in olefin **13** (Scheme 2). Toward this, Mitsunobu inversion of the cyclopentene monoacetate **6** (99% ee) gave alcohol **7**, which was converted to alcohol **8**. Eschenmoser–Claisen rearrangement<sup>11</sup> on **8** with MeC(OMe)<sub>2</sub>NMe<sub>2</sub> afforded amide **9** in 95% yield. Reduction of **9** with DIBAL at –105 °C (liquid nitrogen and MeOH) produced aldehyde **10** in 80% yield, whereas the yield was only 40% at –78 °C. The Corey–Fuchs reaction of **10** followed by debromination with *n*-BuLi afforded the Li anion **12**, which was quenched to produce **11**. We avoided the direct use of the anion **12** for alkylation with C<sub>5</sub>H<sub>11</sub>I because of the possible competition with *n*-BuBr generated *in situ* (from *n*-BuLi). Thus, alkylation of **11** with C<sub>5</sub>H<sub>11</sub>I under the given conditions afforded **13** in 86% yield. Previously, similar intermediates possessing the alkoxy group and the side chain at C11 and C12, respectively, have been synthesized with the 2–4:1<sup>5b,7</sup> and 9:1<sup>6</sup> diastereomeric ratios, whereas our synthesis of **13** is completely stereoselective.

Various aqueous conditions were evaluated for the bromohydration of **13** with NBS (Table 1). The product distributions of the desired bromohydrin **14**, the regioisomer **15**, 4-MeOC<sub>6</sub>H<sub>4</sub>CHO (**22**), and the substrate **13** were determined by <sup>1</sup>H NMR integration and used to assess regioselectivity (**14** over **15**), the extent of decomposition of the products and/or **13**, and conversion. Initial attempts (entries 1–3) indicated the unstable nature of **13** under these conditions since bromohydration of a simple olefin **23**<sup>12</sup> proceeded smoothly (with ca. 2:1 ratios of **24** and **25** in the all entries) (eq 3). Gratifyingly, further investigation in


Table 1. Bromohydration of Olefin **13**

$\text{13} \xrightarrow[\text{0 °C to rt, 12 h}]{\text{NBS (3 equiv), solvent, H}_2\text{O (4:1)}} \text{14} + \text{15} + \text{4-MeOC}_6\text{H}_4\text{CHO (22)}$				
entry	purity grade of NBS	additive <sup>a</sup>	solvent <sup>b</sup>	14:15:13:22
1	purchased	—	acetone	— <sup>c</sup>
2	purchased	—	DMSO	52:<10:14:24 <sup>d</sup>
3	purchased	NaHCO <sub>3</sub>	DMSO	15:<10:7:68 <sup>d</sup>
4	purchased	pyridine	DMSO	74:15:9:2
5	recrystallized	pyridine	DMSO	91(81) <sup>e</sup> :5:2:2
6	recrystallized	—	DMSO	67:26:7:0
7	recrystallized	NaHCO <sub>3</sub>	DMSO	21:<10:20:49 <sup>d</sup>
8	recrystallized	Et <sub>3</sub> N <sup>f</sup>	DMSO	0:0:11:89

<sup>a</sup>6 equiv. <sup>b</sup>Solvent/H<sub>2</sub>O (4:1). <sup>c</sup>Unidentified compounds. <sup>d</sup>Unidentified compounds were also produced. <sup>e</sup>Isolated yield. <sup>f</sup>A similar result with *i*-Pr<sub>2</sub>NEt.

aqueous DMSO disclosed acceleration of the reaction by pyridine (entry 4). Furthermore, the use of recrystallized NBS with pyridine produced **14** with high regioselectivity and product selectivity in 81% isolated yield (entry 5, **14/15** = 18:1). In contrast, the use of recrystallized NBS alone (without pyridine) reduced the regioselectivity (entry 6), while its use in the presence of other bases, such as NaHCO<sub>3</sub>, Et<sub>3</sub>N, and *i*-Pr<sub>2</sub>NEt, retarded or prevented the reaction (entries 7 and 8, footnote f). These results suggest the slightly acidic conditions realized by HBr (generated *in situ*) and pyridine probably assist the nucleophilic attack by DMSO and/or decomposition of the sulfoxonium ion to bromohydrin **14**. The <sup>1</sup>H NMR analysis of **14** showed it to be a 4:1 diastereomeric ratio (dr) though this ratio had no meaning for further transformation. Indeed, this diastereomeric mixture was subjected to oxidation with PCC to afford ketone **16**

(93%), which was a 3:2 diastereomeric mixture by  $^1\text{H}$  NMR analysis ( $\delta$  4.31 (d) and 4.61 (d) ppm for the major and minor isomers).



<sup>a</sup>DMSO, H<sub>2</sub>O (4:1), 0 °C to rt, 12 h.

Among the possible methods for conversion of  $\alpha$ -bromoketones to enolates, organometal–bromine exchange<sup>14</sup> was examined for the present investigation, whereas the radical–bromine exchange<sup>15</sup> was not considered because of the presence of a triple bond which is generally radical-sensitive. The other possible two-step procedures<sup>8</sup> (formation of an enol derivative followed by regeneration of enolate) were also excluded from our examination. First, EtMgBr–Br exchange of a model  $\alpha$ -bromocyclopentanone **26a** ( $n = 5$ ) was attempted according to the previous generation of enolate from  $\alpha$ -iodocyclohexanones with EtMgBr.<sup>14,16</sup> However, an attempted aldol reaction with aldehyde **27** gave a mixture of unidentified products (Table 2, entry 1). In comparison, cyclohexanone **26b** ( $n = 6$ ) afforded **28b** in good yield (entry 2). The use of  $n$ - and  $t$ -BuLi in place of EtMgBr was also unsuccessful (entries 4 and 6). In contrast, the presence of ZnI<sub>2</sub> in the exchange with  $n$ - and  $t$ -BuLi followed by the aldol reaction with **27** produced aldol **28a** (entries 5 and 7). As the  $t$ -BuLi/ZnI<sub>2</sub> system gave slightly higher product selectivity (**28a** over **29a**) than  $n$ -BuLi/ZnI<sub>2</sub>, combinations of  $t$ -BuLi and other zinc salts were also investigated. The  $t$ -BuLi–Br exchange in the presence of ZnI<sub>2</sub>·TMEDA and ZnX<sub>2</sub> ( $X = \text{Br}, \text{OAc}$ ) proceeded with an efficiency similar to that of entry 7 (entries 8, 10, and 11), whereas ZnCl<sub>2</sub> lowered the

selectivity (**28a/29a**) (entry 9) and Zn(OTs)<sub>2</sub> gave unidentified products (data not shown). Comparable outcomes were also obtained in Et<sub>2</sub>O with  $t$ -BuLi alone and  $t$ -BuLi/ZnX<sub>2</sub> ( $X = \text{I}, \text{Br}$ ) (entries not shown). In contrast, the  $t$ -BuLi–Br exchange of cyclohexanone **26b** ( $n = 6$ ) proceeded cleanly without ZnI<sub>2</sub>, and the subsequent aldol reaction afforded **28b** efficiently (entry 12; cf. entry 13).

Among the several successful combinations of  $t$ -BuLi and the zinc salts,  $t$ -BuLi/ZnI<sub>2</sub> was applied to the real  $\alpha$ -bromoketone **16** because of the comparatively nonhygroscopic nature and the ready-to-use convenience of commercial ZnI<sub>2</sub>. The exchange proceeded well, and the subsequent aldol reaction with epoxyaldehyde **18** (99% ee) (see Supporting Information for the preparation) afforded **19** as a diastereomeric mixture at C7 (and C8). Dehydration of **19** via mesylate according to the procedure developed by us<sup>3</sup> for the synthesis of PECPC afforded exoenone **20** as the sole product in 48% yield over three steps. The acetylene in **20** was reduced to the *cis* olefin, and the TBS group was removed to produce alcohol **21** in 82% yield.<sup>17</sup> Finally, a two-step oxidation of **21** furnished acid **3**. The  $^1\text{H}$  NMR spectrum of **3** was consistent with that reported.<sup>5b</sup>


The ZnI<sub>2</sub>-assisted protocol for  $t$ -BuLi–Br exchange (Table 2, entry 7) was applied to various  $\alpha$ -bromoketones. Cyclopentanones **26c–e** possessing *i*-Pr, *t*-Bu, and Ph substituents underwent the exchange, and the subsequent aldol reaction with Ph(CH<sub>2</sub>)<sub>2</sub>CHO (**27**) afforded aldols **28c–e** in good yields (Scheme 3, eq 4). Similarly, the enolate was derived from **26a** and the aldol reaction with *c*-C<sub>6</sub>H<sub>11</sub> and PhCHO furnished aldols **28f** and **28g**, respectively. In contrast, the  $t$ -BuLi–Br exchange of acyclic ketone **26h** was accomplished without ZnI<sub>2</sub> and the aldol reaction with **27** afforded aldol **28h** in good yield (eq 5).

In summary, the PMB ether of 5,6-epoxyisoprostane E2 **3** was synthesized in 11.6% overall yield through bromohydration of **13** and the subsequent aldol reaction of  $\alpha$ -bromocyclopentanone **16**. Furthermore, the  $t$ -BuLi–Br

Table 2. Aldol Reaction of Model Bromoketones

entry	ketone <sup>a</sup>	$n$	RM (equiv)	additive (equiv)	solvent	temp <sup>1</sup> (°C)	temp <sup>2</sup> (°C)	28:29	yield of 28 (%)
1	<b>26a</b>	5	EtMgBr (1.1)	—	THF	0	0	— <sup>b,c</sup>	—
2	<b>26b</b>	6	EtMgBr (1.1)	—	THF	0	0	98:2	71
3	<b>26a</b>	5	EtMgBr (1.1)	ZnX <sub>2</sub> <sup>d</sup> (2)	THF	−78	−78	— <sup>b</sup>	—
4	<b>26a</b>	5	$n$ -BuLi (2.2)	—	THF	−78	−78	— <sup>b</sup>	—
5	<b>26a</b>	5	$n$ -BuLi (2.2)	ZnI <sub>2</sub> <sup>e</sup> (2)	THF	−78	−78	95:5	nd <sup>f</sup>
6	<b>26a</b>	5	$t$ -BuLi (2.2)	—	THF	−78	−78	— <sup>b</sup>	—
7	<b>26a</b>	5	$t$ -BuLi (2.2)	ZnI <sub>2</sub> (2)	THF	−78	−78 <sup>g</sup>	99:1	70
8	<b>26a</b>	5	$t$ -BuLi (2.2)	ZnBr <sub>2</sub> (2)	THF	−78	−78	98:2	67
9	<b>26a</b>	5	$t$ -BuLi (2.2)	ZnCl <sub>2</sub> (2)	THF	−78	−78	87:13	nd <sup>f</sup>
10	<b>26a</b>	5	$t$ -BuLi (2.2)	ZnI <sub>2</sub> ·TMEDA (2)	THF	−78	−78	99:1	69
11	<b>26a</b>	5	$t$ -BuLi (2.2)	Zn(OAc) <sub>2</sub> (2)	THF	−78	−78	97:3	61
12	<b>26b</b>	6	$t$ -BuLi (2.2)	—	THF	−78	−78	99:1	65
13	<b>26b</b>	6	$t$ -BuLi (2.2)	ZnI <sub>2</sub> <sup>h</sup> (2)	THF	−78	−78	95:5	62

<sup>a</sup>Mixture of ca. 1:1 diastereomers. <sup>b</sup>Complex mixture was obtained. <sup>c</sup>Reaction at −78 °C also gave a complex mixture. <sup>d</sup> $X = \text{Cl}, \text{Br}, \text{I}$ . <sup>e</sup>ZnBr<sub>2</sub> and ZnCl<sub>2</sub> produced a 91:9 ratio of **28a:29a** and a complex mixture, respectively. <sup>f</sup>Not determined. <sup>g</sup>Aldol reaction at 0 °C gave a complex mixture. <sup>h</sup>ZnBr<sub>2</sub> produced a 94:6 ratio of **28b:29b** in 60% yield, whereas ZnCl<sub>2</sub> gave a complex mixture.

Scheme 3. *t*-BuLi-Br Exchange and Aldol Reaction<sup>a,b</sup><sup>a</sup>*t*-BuLi (2.2 equiv), ZnI<sub>2</sub> (2 equiv), and RCHO (1.3 equiv) were used.<sup>b</sup> Diastereomeric ratios of 26a,c-e were 1:1, 4:1, 6:1, and 1:1.

exchange in the presence of ZnI<sub>2</sub> was successfully applied to several  $\alpha$ -bromocyclopentanones.

## ■ ASSOCIATED CONTENT

## S Supporting Information

Experimental procedures and spectral data of compounds described herein. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

## Corresponding Author

\*E-mail: [ykobayas@bio.titech.ac.jp](mailto:ykobayas@bio.titech.ac.jp).

## Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid for Scientific Research from MEXT, Japan. Cyclopentenone (converted to 23) was kindly gifted by Zeon Corporation, Jpn.

## ■ REFERENCES

- (1) (a) Jahn, U.; Galano, J.-M.; Durand, T. *Angew. Chem., Int. Ed.* **2008**, *47*, 5894–5955. (b) Leitinger, N. *Mol. Nutr. Food Res.* **2005**, *49*, 1063–1071. (c) Navab, M.; Ananthramaiiah, G. M.; Reddy, S. T.; Van Lenten, B. J.; Ansell, B. J.; Fonarow, G. C.; Vahabzadeh, K.; Hama, S.; Hough, G.; Kamranpour, N.; Berliner, J. A.; Lusis, A. J.; Fogelman, A. M. *J. Lipid Res.* **2004**, *45*, 993–1007.
- (2) (a) Watson, A. D.; Leitinger, N.; Navab, M.; Faull, K. F.; Hörmkö, S.; Witztum, J. L.; Palinski, W.; Schwenke, D.; Salomon, R. G.; Sha, W.; Subbanagounder, G.; Fogelman, A. M.; Berliner, J. A. *J. Biol. Chem.* **1997**, *272*, 13597–13607. (b) Watson, A. D.; Subbanagounder, G.; Welsbie, D. S.; Faull, K. F.; Navab, M.; Jung, M. E.; Fogelman, A. M.; Berliner, J. A. *J. Biol. Chem.* **1999**, *274*, 24787–24798. (c) Subbanagounder, G.; Wong, J. W.; Lee, H.; Faull, K. F.; Miller, E.; Witztum, J. L.; Berliner, J. A. *J. Biol. Chem.* **2002**, *277*, 7271–7281.
- (3) Acharya, H. P.; Kobayashi, Y. *Angew. Chem., Int. Ed.* **2005**, *44*, 3481–3484.
- (4) (a) Acharya, H. P.; Kobayashi, Y. *Tetrahedron Lett.* **2005**, *46*, 8435–8438. (b) Acharya, H. P.; Miyoshi, K.; Kobayashi, Y. *Org. Lett.* **2007**, *9*, 3535–3538. (c) Acharya, H. P.; Miyoshi, K.; Takashima, Y.; Ogawa, N.; Kobayashi, Y. *Heterocycl.* **2008**, *76*, 1181–1189.
- (5) (a) Jung, M. E.; Berliner, J. A.; Angst, D.; Yue, D.; Koroniak, L.; Watson, A. D.; Li, R. *Org. Lett.* **2005**, *7*, 3933–3935. (b) Jung, M. E.;

Berliner, J. A.; Koroniak, L.; Gugiu, B. G.; Watson, A. D. *Org. Lett.* **2008**, *10*, 4207–4209.

(6) Egger, J.; Bretscher, P.; Freigang, S.; Kopf, M.; Carreira, E. M. *Angew. Chem., Int. Ed.* **2013**, *52*, 5382–5385.

(7) Zhong, W.; Springstead, J. R.; Al-Mubarak, R.; Lee, S.; Li, R.; Emert, B.; Berliner, J. A.; Jung, M. E. *J. Med. Chem.* **2013**, *56*, 8521–8532.

(8) Stork, G.; Isobe, M. *J. Am. Chem. Soc.* **1975**, *97*, 4745–4746.

(9) (a) Tsuna, K.; Noguchi, N.; Nakada, M. *Angew. Chem., Int. Ed.* **2011**, *50*, 9452–9455. (b) Tsuna, K.; Noguchi, N.; Nakada, M. *Chem.—Eur. J.* **2013**, *19*, 5476–5486.

(10) (a) Bradbury, R. H.; Walker, K. A. M. *J. Org. Chem.* **1983**, *48*, 1741–1750. (b) Bradbury, R. H.; Walker, K. A. M. *Tetrahedron Lett.* **1982**, *23*, 1335–1338.

(11) Castro, A. M. M. *Chem. Rev.* **2004**, *104*, 2939–3002.

(12) Olefin 23 was prepared from 2-cyclopenten-1-one in 67% yield: (i) NaBH<sub>4</sub>, CeCl<sub>3</sub>·7H<sub>2</sub>O; (ii) PyCO<sub>2</sub>H, DCC, DMAP; (iii) Ph(CH<sub>2</sub>)<sub>3</sub>MgBr/CuI (2:1).

(13) Determination of the stereochemistry of 14 by the <sup>1</sup>H NMR decoupling study was unsuccessful because of the overlap in signals.

(14) Aoki, Y.; Oshima, K.; Utimoto, K. *Chem. Lett.* **1995**, 463–464.

(15) Nozaki, K.; Oshima, K.; Utimoto, K. *Bull. Chem. Soc. Jpn.* **1991**, *64*, 403–409.

(16) William, A. D.; Kobayashi, Y. *J. Org. Chem.* **2002**, *67*, 8771–8782.

(17) The <sup>1</sup>H and <sup>13</sup>C NMR spectra of 21 were consistent with those scanned,<sup>5b</sup> and the <sup>13</sup>C NMR data were revised.